AERI Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is engaged in the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

$15.25  +0.01 (0.07%)
As of 11/18/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  10/25/2013
Outstanding shares:  49,417,407
Average volume:  1,215,184
Market cap:   $331,122,624
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BFRTDG1
Valuation   (See tab for details)
PE ratio:   -10.96
PB ratio:   29.79
PS ratio:   1.65
Return on equity:   54.68%
Net income %:   -34.20%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy